Alkermes plc. Debt Securities, Held-to-maturity, Sold, Realized Gain (Loss)
Alkermes plc. (ALKS) reported Debt Securities, Held-to-maturity, Sold, Realized Gain (Loss) of $0 for the 12-month period ending 2013-03-31, per its 10-K filed 2013-05-23.
Discontinued › Income Statement › Other Income
us-gaap:HeldToMaturitySecuritiesSoldSecurityRealizedGainLoss · last filed 2013-05-23
- Alkermes plc. debt securities, held-to-maturity, sold, realized gain (loss) for fiscal 2013 was $0.00.
| Period end | Debt Securities, Held-to-maturity, Sold, Realized Gain (Loss) 12 month |
|---|---|
| 2013-03-31 | $0.00 10-K · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |